Researchers sought to determine the influence of obesity on the transformation of MGUS, an asymptomatic plasma cell neoplasm, to multiple myeloma.
Investigators found black patients with multiple myeloma are less likely to use newer, more advanced treatments such as autologous HSCT or bortezumib, and explored factors contributing to this as well as the impact on this population.
In this study, researchers evaluated whether ruxolitinib, a JAK2 inhibitor that reduces symptoms in patients with myelofibrosis, would improve disease-related symptoms in patients with CLL.
Researchers investigated whether VRd, which has demonstrated significant efficacy in newly diagnosed multiple myeloma, would improve outcomes in patients with previously untreated myeloma who are not planned for immediate ASCT.
Researchers report on an evaluation of the safety and preliminary efficacy of the HDAC6-selective inhibitor ricolinostat in combination with standard proteasome inhibitor therapy for relapsed or refractory multiple myeloma.
Researchers sought to compare the efficacy of O-DHAP with R-DHAP as salvage treatment, followed by autologous hematopoietic cell transplantation.
A study presented at 2016 ASH annual meeting demonstrated that the combination of elotuzumab, lenalidomide, and dexamethasone has potential in patients with high-risk smoldering multiple myeloma, a population that would otherwise not receive treatment.
Administration of beta blockers in patients with newly diagnosed multiple myeloma may be associated with a reduced risk of cancer-specific death.
Thalidomide and lenalidomide are equivalent with respect to survival outcomes in patients with multiple myeloma.
The US FDA has granted approval for additional indications for daratumumab for the treatment of patients with multiple myeloma who have received prior therapies.
A panel of International Myeloma Working Group members presents their review of current data on the potential host-, disease-, and treatment-related risk factors associated with the development of second primary malignancies in patients with multiple myeloma.
In this single-center, open-label, phase 2b trial, researchers determined if adding vorinostat to lenadolimide and dexamethasome would improve outcomes for patients with multiple myeloma refractory to lenalidomide.
Researchers examined the frequency of TKI-induced hemorrhagic colitis among patients with CML treated with dasatinib and evaluated the efficacy of screening with a fecal occult blood test followed by colonoscopy in this patient population.
Abnormal lipid metabolism is observed in patients with CLL, prompting an investigation to determine if prevalence of metabolic syndrome is higher in patients with CLL and whether lipid-lowering medications impact survival.
In this study, researchers sought to improve the safety of panobinostat plus bortezomib and dexamethasone for relapsed or relapsed and refractory multiple myeloma.
The NCCN campaign was developed to ensure the proper administration of vincristine and to render it impossible to accidentally administer the medication into the spinal fluid.
Expression of ROR1 could promote leukemia-cell activation and enhance disease progression in patients with chronic lymphocytic leukemia, according to a study.
A report of an evaluation of the benefit of ibrutinib in relapsed CLL following allogeneic HSCT based on an analysis of data from patients with relapsed CLL who received ibrutinib salvage therapy after allogeneic HSCT.
Results of this data analysis demonstrate the relationship between treatment facility volume and all-cause mortality among patients with multiple myeloma.
Data on neutropenia and infection-related complications in patients with ALL are lacking; therefore, this study focused on identifying the characteristics and risk factors of infection-related complications in children with newly diagnosed ALL.
This study evaluated whether antibacterial prophylaxis effectively reduced the rate of infections overall for patients receiving intensive chemotherapy for relapsed/refractory AML.
Frontline treatment with rituximab plus high-dose sequential chemotherapy with autologous HSCT failed to improve progression-free or overall survival compared with R-CHOP in patients with diffuse large B-cell lymphoma.
Adding daratumumab to lenalidomide and dexamethasone significantly prolonged progression-free survival compared with lenalidomide plus dexamethasone alone in patients with relapsed or refractory multiple myeloma.
Severe fatigue is associated with unemployment and financial problems in survivors of Hodgkin lymphoma, highlighting the need for clinicians to address fatigue in these patients.
Ruxolitinib is an effective long-term treatment option for patients with polycythemia resistant or intolerant to hydroxyurea, according to a study presented at the 2016 European Hematology Association Congress.
In patients with chronic myeloid leukemia in chronic phase, prolonged treatment with imatinib helps to achieve a deeper molecular response over 5 years.
[Blood and Lymphatic Cancer: Targets and Therapy] This research provides a summary of the pathobiology of polycythemia vera, and examines challenges associated with traditional PV treatment options and the clinical data for ruxolitinib.
High platelet counts and hemoglobin/hematocrit levels may be associated with hearing loss in patients with polycythemia vera.
Among patients with myeloproliferative neoplasms, men with primary myelofibrosis diagnosed after 2006 are at the highest risk of developing secondary acute myeloid leukemia (AML).
Infusion reactions during administration of high-dose carmustine as part of the BEAM conditioning regimen are common and do not appear to be reduced by modestly extending the duration of infusion or giving premedications.
- Hypnosis and Its Use in Cancer Treatment
- Ruxolitinib May Improve Symptom Control in Patients With CLL
- 3-drug Regimen With Ricolinostat Active, Safe in Multiple Myeloma
- Lung Cancer Navigator App Aims to Help Patients Understand Disease
- Menopause-specific QoL Changes Associated With Chemoprevention Nonadherence
- Optimal Timing of Influenza Vaccination in Patients Receiving Chemotherapy
- Racial Disparities Persist in Myeloma Treatment Use
- Hypnosis and Its Use in Cancer Treatment
- Longer Dosing Interval of Zoledronic Acid May Be Acceptable for Bone Metastases
- Melanoma Incidence Still on the Rise in Parts of the United States
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|